SG11201913968VA - Proteins binding nkg2d, cd16 and a tumor-associated antigen - Google Patents
Proteins binding nkg2d, cd16 and a tumor-associated antigenInfo
- Publication number
- SG11201913968VA SG11201913968VA SG11201913968VA SG11201913968VA SG11201913968VA SG 11201913968V A SG11201913968V A SG 11201913968VA SG 11201913968V A SG11201913968V A SG 11201913968VA SG 11201913968V A SG11201913968V A SG 11201913968VA SG 11201913968V A SG11201913968V A SG 11201913968VA
- Authority
- SG
- Singapore
- Prior art keywords
- tumor
- associated antigen
- proteins binding
- binding nkg2d
- nkg2d
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549201P | 2017-08-23 | 2017-08-23 | |
| US201762558514P | 2017-09-14 | 2017-09-14 | |
| US201762558510P | 2017-09-14 | 2017-09-14 | |
| US201762558511P | 2017-09-14 | 2017-09-14 | |
| US201762558509P | 2017-09-14 | 2017-09-14 | |
| US201762566828P | 2017-10-02 | 2017-10-02 | |
| US201762581357P | 2017-11-03 | 2017-11-03 | |
| US201762608384P | 2017-12-20 | 2017-12-20 | |
| PCT/US2018/047714 WO2019040727A1 (en) | 2017-08-23 | 2018-08-23 | BINDING PROTEINS FOR NKG2D, CD16 AND ANTIGEN ASSOCIATED WITH A TUMOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201913968VA true SG11201913968VA (en) | 2020-01-30 |
Family
ID=65439284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201913968VA SG11201913968VA (en) | 2017-08-23 | 2018-08-23 | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200231679A1 (es) |
| EP (1) | EP3672993A4 (es) |
| JP (2) | JP2020531525A (es) |
| KR (1) | KR20200038530A (es) |
| CN (1) | CN111315778A (es) |
| AU (1) | AU2018322178A1 (es) |
| BR (1) | BR112020003654A2 (es) |
| CA (1) | CA3072919A1 (es) |
| IL (2) | IL311488A (es) |
| MX (1) | MX2020002036A (es) |
| RU (1) | RU2020111554A (es) |
| SG (1) | SG11201913968VA (es) |
| WO (1) | WO2019040727A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018148445A1 (en) | 2017-02-08 | 2018-08-16 | Adimab, Llc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| US20230073946A1 (en) * | 2020-01-20 | 2023-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Affinity peptide conjugated with antioxidant for protection of proteins from oxidation |
| US20220119534A1 (en) * | 2020-05-06 | 2022-04-21 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and clec12a |
| CN114437214B (zh) * | 2020-11-03 | 2023-06-02 | 南京北恒生物科技有限公司 | 靶向lir1的抗体及其用途 |
| US20240034795A1 (en) * | 2020-12-31 | 2024-02-01 | Innovent Biologics (Suzhou) Co., Ltd. | Protein containing heterodimer antibody fc, and preparation method therefor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001071005A2 (en) * | 2000-03-24 | 2001-09-27 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| EP1909832A4 (en) * | 2005-06-29 | 2010-01-13 | Univ Miami | ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY |
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| KR101571027B1 (ko) * | 2006-06-12 | 2015-11-23 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 효과기 기능을 갖는 단일쇄 다가 결합 단백질 |
| CN101945893B (zh) * | 2007-12-14 | 2015-02-25 | 诺沃-诺迪斯克有限公司 | 抗人nkg2d抗体及其用途 |
| WO2010017103A2 (en) * | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| KR102561553B1 (ko) * | 2013-03-15 | 2023-07-31 | 젠코어 인코포레이티드 | 이형이량체 단백질 |
| DE102013019352A1 (de) * | 2013-11-13 | 2015-09-17 | Elke Pogge Von Strandmann | Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort |
| SG11201606583VA (en) * | 2014-03-05 | 2016-09-29 | Ucl Business Plc | Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region |
| CN107614522A (zh) * | 2015-01-14 | 2018-01-19 | 指南针制药有限责任公司 | 多特异性免疫调节性抗原结合构建体 |
| CN107530424A (zh) * | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| EP3374389A1 (en) * | 2015-11-13 | 2018-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| US20200048345A1 (en) * | 2015-12-28 | 2020-02-13 | Innate Pharma | Multispecific antigen binding proteins |
| WO2017124002A1 (en) * | 2016-01-13 | 2017-07-20 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| MA47465A (fr) * | 2017-02-10 | 2019-12-18 | Dragonfly Therapeutics Inc | Protéines fixant le bcma, le nkg2d et le cd16 |
-
2018
- 2018-08-23 BR BR112020003654-4A patent/BR112020003654A2/pt unknown
- 2018-08-23 IL IL311488A patent/IL311488A/en unknown
- 2018-08-23 CA CA3072919A patent/CA3072919A1/en active Pending
- 2018-08-23 EP EP18848423.2A patent/EP3672993A4/en active Pending
- 2018-08-23 WO PCT/US2018/047714 patent/WO2019040727A1/en active Application Filing
- 2018-08-23 AU AU2018322178A patent/AU2018322178A1/en active Pending
- 2018-08-23 SG SG11201913968VA patent/SG11201913968VA/en unknown
- 2018-08-23 JP JP2020511319A patent/JP2020531525A/ja active Pending
- 2018-08-23 CN CN201880054953.2A patent/CN111315778A/zh active Pending
- 2018-08-23 RU RU2020111554A patent/RU2020111554A/ru unknown
- 2018-08-23 US US16/639,150 patent/US20200231679A1/en not_active Abandoned
- 2018-08-23 MX MX2020002036A patent/MX2020002036A/es unknown
- 2018-08-23 KR KR1020207007908A patent/KR20200038530A/ko not_active Application Discontinuation
-
2020
- 2020-02-16 IL IL272706A patent/IL272706A/en unknown
-
2023
- 2023-02-24 JP JP2023027219A patent/JP2023062184A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3672993A4 (en) | 2021-10-27 |
| EP3672993A1 (en) | 2020-07-01 |
| JP2023062184A (ja) | 2023-05-02 |
| MX2020002036A (es) | 2020-03-24 |
| KR20200038530A (ko) | 2020-04-13 |
| CA3072919A1 (en) | 2019-02-28 |
| WO2019040727A1 (en) | 2019-02-28 |
| BR112020003654A2 (pt) | 2020-11-17 |
| JP2020531525A (ja) | 2020-11-05 |
| RU2020111554A3 (es) | 2022-01-19 |
| IL311488A (en) | 2024-05-01 |
| CN111315778A (zh) | 2020-06-19 |
| AU2018322178A1 (en) | 2020-02-20 |
| RU2020111554A (ru) | 2021-09-23 |
| IL272706A (en) | 2020-04-30 |
| US20200231679A1 (en) | 2020-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280673A (en) | Proteins that bind nkg2d, cd16, and tumor-associated antigen | |
| IL281323A (en) | Proteins that bind D2NKG, 16CD, and tumor-associated antigen | |
| IL272706A (en) | Proteins that bind D2NKG, 16CD, and tumor-associated antigen | |
| IL270803A (en) | NKG2D, CD16 and tumor-associated antigen binding protein | |
| IL268755A (en) | HER2, NKG2D, and CD16 binding proteins | |
| IL270801A (en) | NKG2D, CD16 and tumor-associated antigen binding protein | |
| MX2020000960A (es) | Anticuerpos anti-tigit. | |
| IL270794A (en) | NKG2D binding protein, CD16 and ROR1 or ROR2 | |
| IL268567A (en) | BCMA, NKG2D and CD16 binding proteins | |
| IL281305A (en) | Proteins that bind CD16, NKG2D, and CCR4, EGFR, or PD-L1 | |
| ZA202003641B (en) | Antibodies binding ctla-4 and uses thereof | |
| IL268790A (en) | CD33, NKG2D and CD16 binding proteins | |
| IL280618A (en) | Proteins that bind NKG2D, CD16 and tumor-associated antigen | |
| IL280656A (en) | Multispecific binding proteins that bind HER2, NKG2D, and CD16 and methods of use | |
| IL268574A (en) | proteins that bind psma, nkg2d, and cd16 | |
| IL268766A (en) | Proteins that bind NKG2D, CD123, and CD16 | |
| IL268768A (en) | Proteins binding gd2, nkg2d and cd16 | |
| IL272374A (en) | NKG2D, CD16, and FLT3 binding proteins | |
| SG11202002590VA (en) | Bispecific antibodies binding alk-1 and bmpr-2 | |
| SG11202011139YA (en) | Protein binding nkg2d, cd16 and a fibroblast activation protein | |
| EP3790585A4 (en) | NKG2D, CD16 AND TUMOR ASSOCIATED ANTIGEN BINDING PROTEIN | |
| ZA201906821B (en) | Anti-jagged1 antigen binding proteins | |
| ZA201905273B (en) | Proteins binding psma, nkg2d and cd16 |